ENDO-205: A New Way of Thinking About Endometriosis

For generations, women with endometriosis have often been offered versions of the same difficult tradeoff: manage pain, suppress the hormonal environment that helps lesions remain active, or undergo surgery to remove visible disease. These approaches can help—sometimes substantially—but they do not work for everyone, symptoms can return, and some options conflict with pregnancy goals or bring burdensome side effects.

ENDO-205 is exciting because its developers are asking a different question: what if a medicine could selectively enter endometriosis tissue and interrupt a non-hormonal cellular program that helps lesions persist?

That is the source of the “breakthrough” language. ENDO-205 is being developed as a precision peptide that would target diseased tissue while leaving healthy tissue and normal ovarian hormone cycling comparatively undisturbed. In NIH project records, investigators report lesion regression and disappearance without altered estrous cycling in preclinical work.

The public conversation around ENDO-205 is not driven by treatment testimonials; the candidate has not yet produced published human efficacy results. It is driven by recognition. Women hear “non-hormonal,” “targets the lesions,” and “designed to spare healthy tissue,” and immediately understand what those goals could mean after years of being told that disabling pain was simply a bad period.

“I want more than symptom control.”

Many people living with endometriosis describe cycling through pain relief, hormonal suppression, and surgery while the underlying disease remains a recurring presence. ENDO-205 resonates because it is framed as disease-modifying rather than only symptom-managing. Whether it can deliver that outcome in humans remains unproven.

“I do not want my only choices to be hormones or surgery.”

Hormonal medicines and surgery are evidence-based options and should not be dismissed. But fertility plans, side effects, contraindications, recurrence, and individual response can make those choices complicated. A genuinely effective non-hormonal option would fill a major gap.

“Go after the lesion, not the whole system.”

The most relatable description of ENDO-205 is precision rather than suppression: a peptide designed to be taken up selectively by diseased tissue and act inside those cells. That selectivity is a development goal supported by reported preclinical work, not yet a demonstrated benefit in patients.

The World Health Organization estimates that endometriosis affects about 10% of reproductive-age women—approximately 190 million worldwide. A 2025 clinical review estimated that the condition affects nearly 9 million women in the United States.

Worldwide

About 190 million reproductive-age women, or roughly 1 in 10.

United States

Nearly 9 million women during their reproductive years, according to a 2025 review.

Time to diagnosis

Published reviews report that diagnosis is commonly delayed for years; estimates vary by country, population, and how delay is measured.

The numbers alone do not capture the burden. Endometriosis can involve severe menstrual pain, chronic pelvic pain, painful sex, bowel or bladder symptoms, heavy bleeding, fatigue, infertility, anxiety, depression, missed work, disrupted education, and social isolation. It can also affect transgender men and nonbinary people who menstruate.

Endometriosis is an estrogen-dependent inflammatory disease, but it is not only a hormone problem and it is not simply misplaced uterine lining. Lesions are biologically active tissue interacting with inflammation, nerves, blood vessels, fibrosis, immune signaling, and pathways involved in cell survival, migration, and invasion.

1. 1

   Pain management

   Anti-inflammatory medicines and other pain strategies may reduce symptoms, but pain relief does not necessarily remove lesions or change disease biology.

2. 2

   Hormonal suppression

   Combined hormonal contraceptives, progestins, GnRH agonists or antagonists, and other hormonal approaches can reduce pain and lesion activity. They can also have side effects, may not suit someone trying to conceive, and symptoms may recur after treatment stops.

3. 3

   Surgery

   Surgery can diagnose disease and remove lesions, adhesions, or scar tissue. Outcomes depend on disease extent and surgical context, and recurrence or persistent pain can still occur. Even hysterectomy is not a guaranteed cure.

ENDO-205 does not prove those approaches were based on a false understanding. It represents a possible expansion of the model: from treating the hormonal environment or mechanically removing disease to targeting a lesion’s own intracellular survival and invasion machinery.

Public NIH records describe ENDO-205 as targeting a downstream component of a pathway involved in endometriosis pathogenesis, migration, and invasion. Those records also include beta-catenin among the project’s scientific terms. Broader research has connected abnormal Wnt/β-catenin signaling with lesion-cell proliferation, migration, invasion, fibrosis, and resistance to normal cell-death signals.

1. 1

   Find the diseased tissue

   The platform is designed so the peptide is selectively absorbed by endometriosis tissue. This is a central sponsor and investigator claim from preclinical development; the degree of selectivity in humans is not yet known.

2. 2

   Reach an intracellular target

   Peptides can be engineered as delivery-and-action molecules. ENDO-205 is intended to enter diseased cells and inhibit a non-hormonal pathway component involved in lesion behavior. Public sources do not fully disclose the proprietary sequence or every molecular interaction.

3. 3

   Interrupt persistence rather than suppress ovarian function

   In preclinical reporting, the goal is lesion regression without altering normal reproductive cycling. This is why the candidate is described as potentially disease-modifying and why fertility-preserving implications are of such interest—but fertility outcomes have not been established in humans.

• NIH-funded preclinical program

  Investigators report lesion regression without altered cycling

  The fiscal-year 2025 NIH project abstract says earlier SBIR milestones generated data supporting efficacy without observed toxicities and describes selective absorption in endometriosis tissue, lesion regression or disappearance, and no alteration of estrous cyclicity. These are investigator-reported preclinical findings in a grant record, not peer-reviewed human trial results.

• Sponsor-reported GLP toxicology

  No safety signals reported before IND clearance

  EndoCyclic reported no safety signals in its Good Laboratory Practice toxicology studies. FDA allowed the IND to proceed to clinical investigation, which means the proposed initial study was not placed on clinical hold based on the submitted package. It does not mean the drug has been proven safe for patients or for long-term use.

• Planned Phase 1 · healthy volunteersNo result yet

  The first human question is safety—not whether it cures endometriosis

  The March 2026 announcement says the company plans a Phase 1 study in healthy premenopausal women of reproductive age. Early Phase 1 research generally focuses on safety, tolerability, and how the body handles a candidate. A study in healthy volunteers cannot by itself demonstrate lesion elimination or symptom relief in women with endometriosis.

• Human efficacy evidenceNo result yet

  No published patient results in the reviewed sources

  The sources reviewed for this page do not provide completed clinical data showing that ENDO-205 reduces pain, shrinks lesions, improves fertility, prevents recurrence, or replaces surgery in people. Those are the decisive questions for later-stage trials.

Non-hormonal

It is designed to avoid suppressing ovarian hormone function, potentially opening an option for people who cannot tolerate or do not want hormonal therapy.

Lesion-directed

It aims at diseased tissue rather than broadly changing the body’s hormonal environment.

Disease-modifying goal

The development goal is regression of lesions, not only reducing the pain signals those lesions generate.

Cycling preserved

Sparing normal cycling could be important in women’s health, but reproductive safety and fertility outcomes still require human evidence.

A different disease model

It treats endometriosis as active, targetable tissue biology involving survival and invasion pathways—not merely a painful period or an estrogen level to suppress.

The honest description today is potential breakthrough. ENDO-205 has crossed an important regulatory threshold from preclinical development to permitted human investigation. It has not crossed the much higher threshold of showing meaningful patient benefit.

People with severe pelvic pain, heavy bleeding, pain during sex, bowel or bladder symptoms, fatigue, or difficulty becoming pregnant deserve a clinical evaluation. Current diagnosis may be based on symptoms, examination, ultrasound, or MRI; laparoscopy is not always required before treatment begins.

1. 1

   Take symptoms seriously

   Debilitating period pain is not something a patient should simply be expected to endure.

2. 2

   Match care to goals

   Treatment choices depend on pain, disease extent, side effects, contraindications, pregnancy plans, prior care, and individual preference.

3. 3

   Keep ENDO-205 in its lane

   It is a clinical-development candidate, not a substitute for diagnosis, an approved therapy, or a product available through peptide sellers.